AML, Adult
Conditions
Brief summary
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Detailed description
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.
Interventions
BIOLOGICALBiological characterization of AML with MECOM or atypical 3q26 rearrangements
Peripheral blood and bone marrow withdrawal
Sponsors
Gruppo Italiano Malattie EMatologiche dell'Adulto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable | At baseline | To assess the number of regulators or effectors of MECOM/EVI1 |
Countries
Italy
Contacts
Primary ContactPaola Fazi
Backup ContactEnrico Crea
Outcome results
None listed